Department of Surgery, Faculty of Medicine, Federal University of Rio de Janeiro (UFRJ), Rua Rodolpho Paulo Rocco, 255-Cidade Universitária, Ilha do Fundão, Rio de Janeiro, RJ, Brazil 21941-902.
Internal Medicine Department, Botucatu Medical School, Sao Paulo State University (UNESP), Av. Prof. Mario Rubens Guimaraes Montenegro, S/N, Botucatu, SP, Brazil 18618-687.
Biomed Res Int. 2020 Oct 17;2020:1487593. doi: 10.1155/2020/1487593. eCollection 2020.
We aimed to identify prognostic factors for survival and recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) for patients with HCC and hepatitis C virus-related cirrhosis (HCV-cirrhosis).
This retrospective cohort study followed all adult patients with HCV-cirrhosis who underwent LT because of HCC or had incidental HCC identified through pathologic examination of the explanted liver at a university hospital in Rio de Janeiro, Brazil, over 11 years (1998-2008). We used Cox regression models to assess the following risk factors regarding HCC recurrence or death after LT: age, Model for End-stage Liver Disease score, Child-Pugh classification, alpha-fetoprotein (AFP), whether patients had undergone locoregional treatment before transplantation, the number of packed red blood cell units (PRBCU) transfused during surgery, the number and size of HCC lesions in the explanted liver, and the presence of microvascular invasion and necrotic areas within HCC lesions.
Seventy-six patients were followed up for a median (interquartile range (IQR)) of 4.4 (0.7-6.6) years. Thirteen (17%) patients had HCC recurrence during the follow-up period, and 26 (34%) died. The median survival time was 6.6 years (95% CI: 2.4-12.0), and the 5-year survival was 52.5% (95% CI: 42.3-65.0%). The final regression model for overall survival included four variables: age (hazard ratio (HR): 1.02, 95% CI: 0.96-1.08, = 0.603), transplantation waiting time (HR: 1.00, 95% CI: 1.00-1.00, = 0.190), preoperative AFP serum levels (HR: 1.01, 95% CI: 1.00-1.02, = 0.006), and whether >4 PRBCU were transfused during surgery (HR: 1.15, 95% CI: 1.05-1.25, = 0.001). The final cause-specific Cox regression model for HCC recurrence included only microvascular invasion (HR: 14.86, 95% CI: 4.47-49.39, < 0.001).
In this study of LT for HCV-cirrhosis, preoperative AFP levels and the number of PRBCU transfused during surgery were associated with overall survival, whereas microvascular invasion with HCC recurrence.
我们旨在确定丙型肝炎病毒相关肝硬化(HCV 肝硬化)患者接受肝移植(LT)后肝癌(HCC)生存和复发的预后因素。
这项回顾性队列研究随访了在巴西里约热内卢的一所大学医院接受 LT 的所有 HCV 肝硬化成年 HCC 患者或通过对供体肝进行病理检查发现 HCC 的患者。研究时间为 11 年(1998-2008 年)。我们使用 Cox 回归模型评估了以下与 LT 后 HCC 复发或死亡相关的风险因素:年龄、终末期肝病模型评分、Child-Pugh 分级、甲胎蛋白(AFP)、患者在移植前是否接受了局部区域治疗、手术期间输注的红细胞单位数(PRBCU)、切除的肝内 HCC 病变的数量和大小,以及 HCC 病变内微血管侵犯和坏死区的存在。
76 例患者的中位(四分位距(IQR))随访时间为 4.4(0.7-6.6)年。13 例(17%)患者在随访期间出现 HCC 复发,26 例(34%)死亡。中位生存时间为 6.6 年(95%CI:2.4-12.0),5 年生存率为 52.5%(95%CI:42.3-65.0%)。总生存的最终回归模型包括四个变量:年龄(风险比(HR):1.02,95%CI:0.96-1.08,=0.603)、移植等待时间(HR:1.00,95%CI:1.00-1.00,=0.190)、术前 AFP 血清水平(HR:1.01,95%CI:1.00-1.02,=0.006)和手术期间是否输注了>4 PRBCU(HR:1.15,95%CI:1.05-1.25,=0.001)。HCC 复发的最终特定原因 Cox 回归模型仅包括微血管侵犯(HR:14.86,95%CI:4.47-49.39,<0.001)。
在这项 HCV 肝硬化 LT 研究中,术前 AFP 水平和手术期间输注的 PRBCU 数量与总生存相关,而微血管侵犯与 HCC 复发相关。